Lv6
1980 积分 2023-05-08 加入
Lipoprotein (a): A new target for pharmacological research and an option for treatment
9天前
已完结
Target Populations for Novel Triglyceride-Lowering Therapies
13天前
已完结
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
14天前
已完结
Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients
14天前
已完结
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial
15天前
已完结
Present therapeutic role of cholesteryl ester transfer protein inhibitors
15天前
已完结
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial
15天前
已完结
Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?
16天前
已完结
Cholesteryl Ester Transfer Protein (CETP) Variations in Relation to LipidProfiles and Cardiovascular Diseases: An Update
16天前
已完结
The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα
20天前
已完结
皖公网安备34019202002308
